Sarah Gheuens, an officer of Agios Pharmaceuticals, Inc., filed a Form 144 notice on October 26, 2026, proposing to sell 7,866 shares of common stock acquired through a stock option exercise on the same date.

Key Highlights

  • Proposed sale: 7,866 shares of Agios Pharmaceuticals common stock, with an aggregate market value of $296,467.97, according to the filing.
  • Acquisition method: The shares were acquired on October 26, 2026, via a stock option exercise from the issuer, with cash payment made on the same date.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is identified as the broker for the proposed sale.
  • Exchange listed: The securities are listed on NASDAQ, and the issuer trades under the filing's registered name Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).
  • 10b5-1 plan in place: The filing indicates a written trading plan was adopted on May 1, 2026.
  • Shares outstanding: The filing states 59,701,882 shares of common stock were outstanding at the time of notice.
  • Prior sales disclosed: Gheuens sold 500 shares on October 22, 2026 (gross proceeds $18,760.00), 1,489 shares on October 21, 2026 (gross proceeds $55,881.28), and 30,000 shares on August 4, 2026 (gross proceeds $914,283.00) in the three months preceding this notice.

Details of Sarah Gheuens' Proposed Share Sale at Agios Pharmaceuticals

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Sarah Gheuens, identified as an officer of Agios Pharmaceuticals, Inc., proposed to sell 7,866 shares of the company's common stock. The aggregate market value of the shares to be sold was listed as $296,467.97. The proposed approximate date of sale is October 26, 2026, with Morgan Stanley Smith Barney LLC Executive Financial Services named as the executing broker.

The filing discloses that the 7,866 shares were acquired on October 26, 2026, through a stock option exercise from the issuer, with full cash payment made on the same date. The notice also indicates that Gheuens is relying on a Rule 10b5-1 written trading plan, with a plan adoption date of May 1, 2026. The filing's signatory representation states that the seller does not know of any material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed, as of the plan adoption date.

The filing further discloses sales by Gheuens during the three months prior to this notice: 500 shares sold on October 22, 2026 for gross proceeds of $18,760.00; 1,489 shares sold on October 21, 2026 for gross proceeds of $55,881.28; and 30,000 shares sold on August 4, 2026 for gross proceeds of $914,283.00. Agios Pharmaceuticals, Inc. is headquartered at 88 Sidney St., Cambridge, Massachusetts 02139, according to the filing.

What Was Disclosed

A Form 144 notice was filed on October 26, 2026, by Agios Pharmaceuticals officer Sarah Gheuens, covering a proposed sale of 7,866 common shares acquired via stock option exercise, under a Rule 10b5-1 plan adopted May 1, 2026.